AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00704912 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Orlistat/Meal Replacement/Lifestyle Modification
Description: Orlistat will be given at 60 mg three times per day (1 tablet 3 times a day) before meals, i.e., breakfast, lunch, and dinner.
Study NCT00704912 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Loestrin 1/20
Description: Patients will be started on a low dose containing OCP for a continuous 4 month period.
Study NCT00704912 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Combination of treatments
Description: Medications will be administered as described for the other 2 arms.
Study NCT02496962 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: atorvastatin were taken daily for 5 days
Study NCT02496962 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo were taken daily for 5 days
Study NCT02667327 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Granexin gel
Description: Granexin gel contains active pharmaceutical ingredient, aCT1 peptide, for topical application to diabetic foot ulcers once a week for up to 12 weeks or until wound closure, whichever comes first.
Study NCT02667327 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle gel
Description: The vehicle gel formulation is hydroxyethyl cellulose that does not contain the active aCT1 peptide. Vehicle gel will be applied topically to diabetic foot ulcers once a week for up to 12 weeks or until wound closure, whichever comes first.
Study NCT01630850 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allogenic islet cells (human, U. Chicago)
Description: Human allogenic islet cells. Immunosuppression may include remicade, thymoglobulin,prograf, solu-medrol, and cellcept. Dosage will vary per patient based on weight. Patients will receive immunosuppression medications while islet cells are functioning.
Study NCT01630850 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intraportal infusion of islet cells
Description: Intraportal infusion of islet cell through the portal vein in the liver.
Study NCT02024282 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Use of C-reactive protein (CRP) point of care test
Study NCT01487161 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FX006
Description: Single 3 mL intra-articular injection
Study NCT01487161 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TCA IR
Description: Single 1 mL intra-articular injection
Study NCT02486770 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Aerucin 2.0mg/kg
Description: IV Aerucin 2.0 mg/kg over 1 hour
Study NCT02486770 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Aerucin 8.0mg/kg
Description: IV Aerucin 8.0 mg/kg over 1 hour
Study NCT02486770 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Aerucin 20.0 mg/kg
Description: IV Aerucin 20 mg/kg over 1 hour
Study NCT03918291 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Addition of whole-body vibration to squat training
Study NCT03918291 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Squat training
Description: squatting exercises for 12 weeks, 3x/week
Study NCT03493893 — intervention group
Intervention type: DEVICE
Intervention: Intermedullary nail
Description: investigate the clinical effects of these design changes from the use of three different IM nail designs in the management of extracapsular hip fractures.
Study NCT04868071 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Exercise
Description: Exercise interventions were carried out over a total of 16 weeks in the mornings (08:00 am-12:00 am) under the supervision of at least two fitness instructors. Participants performed four exercises for lower limbs (Figure 9): 1st) squat on the chair, 2nd) seated unilateral hip flexion, 3rd) seated unilateral knee extension, and 4th) bilateral calf raise with 12-15 submaximal repetitions avoiding fatigue (i.e., inability to complete a repetition in a full range of motion). The number of sets was increased linearly during the first month, such that one set was performed in the 1st week, two sets in the 2nd week, 3 sets in the 3rd week, and 4 sets in the 4th week. Subsequently, participants performed the main exercise period. After a brief warm-up, participants performed the same exercises that were performed during the familiarization period using an adjustable weight vest and ankle weights (DOMYOS®, Shangai, China).
Study NCT02024282 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Brief intervention and parent leaflet
Description: Brief interventions are commonly used to give opportunistic advice, discussion, negotiation or encouragement. Mostly they take between 5 to 10 minutes. We developed a brief intervention: we'll ask the clinicians to ask 3 specific questions, namely Are you concerned?, What exactly concerns you? and Why does this concern you?. This intervention is easy to implement in daily practice and no additional training is required.~We developed a parent information leaflet that gives information about what they can do when their child is ill, which signs are important to follow up and when they really should get advice from a clinician. This could make it easier for them to cope with an ill child. The clinician could use this leaflet to give advice and make clear when they have to re-consult their physician to re-evaluate the child. Our hypothesis is that through creating this safety net, the improper demand for antibiotics could be reduced.
Study NCT02024282 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Finger Pulse Oximeter
Description: All physicians will be asked to perform a measurement of the oxygen saturation on all children and enter the results on the case report form. The selected device is a clip-on system suitable for use in children, which measures oxygen saturation in the capillary blood as well as the pulse rate.
Study NCT02024282 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Finger Pulse Oximeter
Description: All physicians will be asked to perform a measurement of the oxygen saturation on all children and enter the results on the case report form. The selected device is a clip-on system suitable for use in children, which measures oxygen saturation in the capillary blood as well as the pulse rate.
Study NCT03391791 — intervention group
Intervention type: GENETIC
Intervention: Genetically engineered T Cell Receptors
Description: No study drug is administered in this study. Subjects who received lentivirus-mediated genetically engineered T Cell Receptors in a previous trial will be evaluated in this trial for long-term safety and efficacy.
Study NCT00052897 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HspE7
Study NCT03633058 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: oral ketamine dosed twice daily for 5 days
Study NCT02560181 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: HDR brachytherapy
Description: Whole gland salvage
Study NCT03034200 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONC201
Description: 625mg ONC201 will be given on two consecutive days each week
Study NCT02901561 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: misoprostol 200
Study NCT02901561 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: misoprostol 400
Study NCT04413708 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: P3-T PrEP Adherence App
Description: P3-T provides daily PrEP reminders, a medication tracker and calendar, personalized medication adherence strategies, refill reminders, and tailored adherence support messages; social support via a social wall that includes daily discussion prompts; daily quests to build knowledge and skills; a multimedia knowledge center; interactive narrative collections; personalized adherence counseling provided by an adherence counselor via in-app messaging; in-app rewards; a bank account that rewards daily app use by adding or subtracting a small financial reward based on daily app use; and, a user profile that includes a user-selected avatar.
Study NCT02644057 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Milrinone
Description: Patients who meet the inclusion criteria for the study will receive milrinone and patients will be monitored for improvement of the renal function objectively with measures such as Blood urea nitrogen, creatinine , daily urine output and changes in weight
Study NCT02644057 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dobutamine
Description: Patients who meet the inclusion criteria for the study will receive dobutamine and patients will be monitored for improvement of the renal function objectively with measures such as Blood urea nitrogen, creatinine , daily urine output and changes in weight
Study NCT00191698 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: atomoxetine hydrochloride
Study NCT00191698 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT00521352 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active Repetitive Transcranial Magnetic Stimulation (rTMS)
Description: Strong electromagnetic field (\~2Tesla) generated briefly (\~1ms) but repetitively (1Hz) for 30min, five sessions a week for up to eight weeks.
Study NCT00521352 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Repetitive Transcranial Magnetic Stimulation (rTMS)
Description: Generates a field with the same parameters as active rTMS (see active arm for parameters), however, the actual magnetic fields are blocked by an electromagnetic shield built into a sham coil. The field is impeded from stimulating the brain.
Study NCT04511741 — intervention group
Intervention type: OTHER
Intervention: no intervention, it is an observational study.
Description: no intervention, it is an observational study.
Study NCT01813357 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: encapsulated tablet 20mg daily
Study NCT01813357 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo arm included to maintain blinding
Study NCT02362763 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Acupuncture
Description: Patients randomized to the study group received five sessions of acupuncture in a series of points in the lower abdomen, lower back, hands, and feet. This combination of acupoints is believed to impact on the genital area, raise the pain threshold, and counteract inflammation. Control group patients received five sessions of acupuncture at acupoints that are believed to have no influence on the genital area, but are believed to have a general sedative effect.
Study NCT02362763 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Patients randomized to the study group received five sessions of acupuncture in a series of points in the lower abdomen, lower back, hands, and feet. This combination of acupoints is believed to impact on the genital area, raise the pain threshold, and counteract inflammation. Control group patients received five sessions of acupuncture at acupoints that are believed to have no influence on the genital area, but are believed to have a general sedative effect.
Study NCT03292029 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: T50 Calcification Inhibition Test (CIT)
Description: Measurement of predialysis T50 CIT and fetuin-A values in serum of hemodialysis patients
Study NCT01505803 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Zinc supplements
Description: Participants will receive 40 mg of zinc each day for 12 weeks.
Study NCT01505803 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Omega 3 supplements
Description: Participants will receive 2 g of omega 3 fatty acids each day for 12 weeks.
Study NCT01505803 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Placebo supplements
Description: Participants will receive placebo supplements each day for 12 weeks.
Study NCT01505803 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo supplements
Description: Participants will receive placebo supplements each day for 12 weeks.
Study NCT04412239 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient-centred advice on Telephone Consultation in TB Patients:
Description: The primary aim was to assess the efficiency and the satisfaction of the telephone consultation. The COVID-19 pandemic might be an opportunity to review and refine our practices in TB care. For the follow-up of selected patients, telephone consultations may be efficient and cost effective.
Study NCT04143061 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal polysaccharide (serogroups A,C,Y and W) tetanus toxoid conjugate vaccine
Description: Pharmaceutical form: solution for injection; Route of administration: intramuscular, 0.5 mL
Study NCT04143061 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Meningococcal polysaccharide (serogroups A,C,Y and W-135) diphtheria toxoid conjugate vaccine
Description: Pharmaceutical form: sterile aqueous solution; Route of administration: intramuscular, 0.5 mL
Study NCT04143061 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Meningococcal polysaccharide (serogroups A, C, Y and W-135) vaccine
Description: Pharmaceutical form: reconstituted solution for injection; Route of administration: intramuscular, 0.5 mL
Study NCT04143061 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Hepatitis A vaccine
Description: Pharmaceutical form: Suspension for injection in prefilled syringe Route of administration: Intramuscular, 0.5 mL
Study NCT04143061 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hepatitis A vaccine
Description: Pharmaceutical form: Suspension for injection in prefilled syringe Route of administration: Intramuscular, 0.5 mL
Study NCT04143061 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Measles, Mumps, and Rubella Virus Vaccine (MMR)
Description: Pharmaceutical form: Lyophilized powder for injection Route of administration: Subcutaneous or Intramuscular, 0.5 mL
Study NCT04143061 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Measles, Mumps, and Rubella Virus Vaccine (MMR)
Description: Pharmaceutical form: Lyophilized powder for injection Route of administration: Subcutaneous or Intramuscular, 0.5 mL
Study NCT04143061 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pneumococcal 13-valent conjugate vaccine
Description: Pharmaceutical form: Suspension for injection Route of administration: Intramuscular, 0.5 mL
Study NCT04143061 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumococcal 13-valent conjugate vaccine
Description: Pharmaceutical form: Suspension for injection Route of administration: Intramuscular, 0.5 mL
Study NCT04143061 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: DTwP-HepB-Hib-IPV vaccine
Description: Pharmaceutical form: Solution for injection Route of administration: Intramuscular, 0.5 mL
Study NCT04143061 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DTwP-HepB-Hib-IPV vaccine
Description: Pharmaceutical form: Solution for injection Route of administration: Intramuscular, 0.5 mL
Study NCT04143061 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Varicella vaccine
Description: Pharmaceutical form: Sterile powder and diluent for injection in prefilled syringe Subcutaneous, 0.5 mL~Route of administration: Pharmaceutical form:
Study NCT04143061 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Varicella vaccine
Description: Pharmaceutical form: Sterile powder and diluent for injection in prefilled syringe Subcutaneous, 0.5 mL~Route of administration: Pharmaceutical form:
Study NCT00526045 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AUY922 2 mg/m2
Study NCT03238196 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erdafitinib
Description: 4mg - 8mg
Study NCT03238196 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: 125 mg
Study NCT03238196 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: 500 mg
Study NCT03701334 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribociclib
Description: Ribociclib orally taken at 400 mg on days 1 to 21 of a 28-day cycle
Study NCT03701334 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Endocrine Therapy
Description: ET will be administered according to the local clinical guidelines and current local prescribing information
Study NCT03701334 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Endocrine Therapy
Description: ET will be administered according to the local clinical guidelines and current local prescribing information
Study NCT04341012 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Collection of breath sample
Description: Analysis of volatile organic compounds in breath
Study NCT04235062 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ringer's (8.6 g/L sodium chloride, 0.33 g/L calcium chloride, 0.3 g/L potassium chloride) Solution
Description: A 2-hour of infusion of Ringer's (8.6 g/L sodium chloride, 0.33 g/L calcium chloride, 0.3 g/L potassium chloride) solution will be given following completion of the first 3-hour urine collection period: 0.5 liter infused over 10 min followed by 0.5 liter infused over 1 hour 50 minutes.
Study NCT04235062 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous Bolus Furosemide
Description: Following completion of the second 3-hour urine collection period and after the second set of blood and urine samples are obtained, 40 mg of furosemide will be given as an IV bolus.
Study NCT00423865 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: cisplatin (20 mg/m2 intravenously on Days 1, 8, and 15)
Study NCT00423865 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: everolimus
Description: escalating doses of daily RAD001 tablets (per oral or via percutaneous gastrostomy tube, Days 1 -21 of a 28-Day Cycle)
Study NCT00423865 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: gene expression analysis
Description: Each biopsy specimen will be formalin-fixed and paraffin-embedded for IHC, and analysis of p53 and p21 will follow methods previous reported by our group. The avidin-biotin immunoperoxidase technique will be employed.
Study NCT00423865 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunohistochemistry staining method
Description: After the phase 2 recommended dose is established in the phase I portion of the study (Part A), we plan to enroll an additional 6 patients for pharmacodynamic studies (Part B). Entry into Part B requires the patient have tumor tissue which is easily accessible for research biopsy. The patients will be asked to provide written informed consent for the research biopsies. Patients also will be asked to provide written informed consent to allow the use of their tissue for future research studies. The research biopsies are not mandatory for any patient. Patients who do not consent to the research biopsies or who withdraw consent for the research biopsies may still receive RAD001 + cisplatin in the study
Study NCT00423865 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Laboratory data (complete blood count, comprehensive metabolic panel including magnesium) regarding adverse events will be collected on each cisplatin treatment day. Additional adverse event data will be collected at regularly scheduled clinic visits at which history and physical are performed by the investigator (Cycle 1 - Days 1, 8, 15, and 21. Cycle 2 - Days 1 and 15. Cycle 3 and beyond - Day 1)
Study NCT00423865 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: For patients in Part A, research bloods for pharmacokinetics are drawn on Day 1 and Day 8.
Study NCT00423865 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: biopsy
Description: Pre-treatment Research Biopsy: Within 14 days prior to treatment, research biopsy (of primary tumor, metastatic deposit, or involved lymph node) will be performed. Baseline labs should be drawn within 14 days of the research biopsy. The biopsy sample will be formalin-fixed and paraffin-embedded for immunohistochemistry. Post-treatment Research Biopsy: Research biopsy (of primary tumor, metastatic deposit, or involved lymph node) will be requested again for Day 15 of Cycle 1, prior to administration of RAD001 and cisplatin on that day.
Study NCT02922933 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: entinostat
Description: HDAC (histone deacetylase inhibitor)
Study NCT02456883 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gilteritinib
Description: oral
Study NCT02922933 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Omeprazole
Description: Proton pump inhibitor
Study NCT02922933 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Famotidine
Description: Histamine-2 blocker
Study NCT00606944 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: fast-track rehabilitation
Description: fast-track rehabilitation with early ambulation and diet after elective colorectal resection
Study NCT02456883 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 14C-labeled gilteritinib
Description: oral
Study NCT03518060 — intervention group
Intervention type: DRUG
Intervention: JULUCA
Description: JULUCA is a combination of dolutegravir (INSTI) and rilpivirine (NNRTI).